In the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial, ART-naïve patients with CD4 cell counts ≤500 cells/μL had a higher prevalence of CKD than those with higher CD4 cell counts [29]. Here, CD4 is linked to chronic kidney disease.